The Latest Breaking News from MRNA

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

A whale with a lot of money to spend has taken a noticeably bullish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 19 strange trades.

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 13 strange trades.

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Moderna Inc (NASDAQ:MRNA) has released new clinical data on its bivalent (omicron) COVID booster candidate, mRNA-1273.214.  One month after administration in previously vaccinated and boosted participants, a 50 µg booster dose of mRNA-1273.214 elicited potent neutralizing antibody responses against the omicron subvariants BA.4 and BA.5. The company is working on completing regulatory submissions…

Moderna Inc (NASDAQ:MRNA) announced an agreement with the United Kingdom government to establish an mRNA Innovation and Technology Center in the U.K.  Additionally, Moderna plans to expand its presence in the U.K. through investments in R&D activities. Moderna is collaborating with the National Institute for Health Research on a Phase 3 study…

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Moderna Inc (NASDAQ: MRNA) is reportedly planning to evaluate its COVID-19 vaccine in infants aged three months to 6 months.

Moderna (NASDAQ:MRNA) has outperformed the market over the past 10 years by 32.14% on an annualized basis producing an average annual return of 42.94%. Currently, Moderna has a market capitalization of $49.53 billion.

Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine received unanimous backing from the FDA's committee of independent immunization experts for children ages 6 through 17.

Moderna Inc's (NASDAQ:MRNA) COVID-19 vaccine may relate to a higher risk of heart inflammation in some age groups than Pfizer Inc (NYSE:PFE) - BioNTech SE's (NASDAQ:BNTX) shot, Reuters reported citing the Centers for Disease Control and Prevention. Citing recent data, CDC said that the findings on myocarditis and pericarditis, types of heart inflammation linked to both the…